National Consensus Conference on the Pharmacoeconomics of Treatment-Resistant Schizophrenia. Dallas, TX, USA, 1997/10/04.
Although schizophrenia afflicts 1.1% of the U.S. population, it imposes a disproportionately large economic burden due to expenditures for hospitalization, treatment and rehabilitation, and lost productivity.
Cost-of-illness studies, using a variety of methodologies to calculate direct and indirect costs, have estimated that in 1990 the total economic burden of schizophrenia was $32.5 billion.
Of this total, $17.3 billion was attributable to direct medical costs.
By comparison, in the same year the total and direct medical costs for anxiety disorders, which are more than 10 times more prevalent than schizophrenia, were $46.6 billion and $10.7 billion, respectively.
For affective disorders, almost 10 times more prevalent than schizophrenia, the total and direct costs were $30.4 billion and $19.2 billion, respectively.
Effective treatments used early in the course of schizophrenia can help reduce the costs associated with this illness.
Mots-clés Pascal : Schizophrénie, Analyse coût, Economie santé, Chimiothérapie, Traitement, Homme, Psychose
Mots-clés Pascal anglais : Schizophrenia, Cost analysis, Health economy, Chemotherapy, Treatment, Human, Psychosis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0185891
Code Inist : 002B18C06A. Création : 16/11/1999.